



HANSA

BIOPHARMA

Redeye investor event
Commercialization

March 7, 2023

Pierre-Henri Patin

VP Commercial Operations



Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Pierre-Henri Patin M.D

VP Commercial Operations Europe


>20 years of Pharma Experience with more than 15 years in Biotech International Leadership roles

- M.D. degree from Paris Descartes University Paris, France
- 5 years experience at Celgene with GM roles
- 9 years at Vertex International as Regional VP

Joined Hansa Biopharma in December 2020



Key milestones achieved during the last 12 months



Idefirix® (imlifidase) has received conditional approval in the European Union

Low complexity transplants ← → Higher complexity transplants

~70% of patients^{1,2}

15-20% of patients^{1,2}

10-15% of patients^{1,2}



Highly sensitized patients that are likely to be transplanted with a compatible donor

Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs



Actual patient has given consent to provide images

Idefirix® is indicated for

desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.

The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients



Potential patients

imlifidase


¹ EDQM. (2020). International figures on donation and Transplantation 2019
² SRTR Database and individual assessments of allocation systems




The kidney transplantation landscape in Europe and the U.S.

Up to 15% of patients waiting for a new kidney are highly sensitized

Breakdown of the kidney transplant waitlist in U.S. and EU





~50,000 transplants done annually in the U.S. and Europe



*Reported to be impacted by the COVID-19 pandemic

Positive reimbursement decisions received in four of the five largest markets including Italy, U.K., Germany and France (early access)

Market access has now been secured in 11 European countries and procedures are ongoing in nine countries including Spain as the last of the five major European markets




¹Annual kidney transplantations 2019 (pre-Corona)

^{*}Transplantation data is from Global Observatory on Donation and Transplantation, 2019

^{**}Pricing & reimbursement obtained in France on an early access basis


Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation

Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers





**Total 2022 revenue of SEK 155m;
Q4 2022 Revenue amounted to SEK 31m
including SEK 20m in product sales**

Revenue (Q/Q)



Revenue (12M/12M)





HANSA

BIOPHARMA